Contact Us

Featured

Innovation in mRNA capping and streamlined process development for best-in-class mRNA manufacturing

The success of mRNA-based COVID-19 vaccines has triggered a rapid expansion of mRNA vaccines and therapeutics. An essential part of any mRNA therapeutic design is the 5’ cap structure, which is critical to the stability and expression of an mRNA. Learn how next-generation capping strategies impact manufacturing costs, timelines, and complexity. In addition, we will address considerations for process development, synthesis, and scale-up to streamline the mRNA manufacturing process.

Overcoming Critical Barriers when Developing mRNA-based Cell Therapies

There is a robust and promising therapeutic pipeline of mRNA-based cell therapies. This roundtable panel will discuss critical barriers in the drug substance development process for mRNA-based cell therapies. The discussion will include process development lessons learned, insights from analytical development programs, and how manufacturing innovations can help you navigate and overcome these key barriers.

Next-Generation mRNA Design — Increasing mRNA potency with a New Cap Analog

mRNA vaccines and therapeutics are expanding rapidly, fueled in part by the extraordinary distribution and success of the COVID-19 vaccines. An essential part of the success of any mRNA therapeutic is the 5’ cap structure, which is critical to the stability and expression of an mRNA.

Getting started with mRNA — Increasing your probability for success

The emergence of mRNA as a versatile platform for therapeutic and vaccine development holds immense promise in reshaping the landscape of molecular medicine. As researchers and biopharmaceutical professionals explore the potential of mRNA-based technologies, a comprehensive understanding of the fundamental principles, techniques, and past insights becomes essential for achieving successful outcomes.

Getting started with mRNA-based therapeutics — Myths, considerations, and characterization

Join the "Getting started with mRNA-based therapeutics" roundtable to explore mRNA challenges, including usability, stability, and technological limits. Gain insights into developmental considerations for clinic-bound constructs. Explore the crucial role of characterizing and analyzing mRNA in the early stages of development.

play

Stealth Mission: Novel mRNA Vaccine Delivery System

The recent success of mRNA vaccines during the COVID pandemic has vaulted this technology from its humble research beginnings to international recognition by the scientific and medical community as a groundbreaking measure in combating a host of diseases. The delivery of mRNA molecules has been dominated by the use of lipid nanoparticles (LNPs). However, while LNPs have proven effective, they provide investigators with several challenges—most importantly, the activation of unwanted cell-mediated immune responses. Alternative mRNA delivery systems offer the capability to stealthily deliver nucleic acids to their target and evade the immune system while generating a potent antigen-specific CD8+ T-cell response.

In this webinar cohosted by GEN and The CRISPR Journal, we will delve into the delivery question surrounding mRNA research and therapeutics. Dr. Helen McCarthy will review the key issues around RNA delivery and describe a novel peptide-based drug delivery system that her company has developed. This system is based on a sequence of 30 amino acids and condenses anionic cargo, like mRNA, irrespective of size, into nanoparticles for highly efficient entry into cells.

play

Chemically Modified mRNA as a Biologic: Developing an Analytical Framework for Success

Developing an analytical framework for success using a chemically modified mRNA can be compared with those for traditional biologics. Though much of the regulatory filing requirements can be compared with those for traditional biologics, others are not yet well defined. As such, it’s especially important that control on quality and consistency is maintained to ensure efficacy, purity, and safety.

Like traditional biologic products and processes, mRNA-based products require controls on:

  • Quality of the starting material (including cell banking)
  • Consistency of manufacturing processes
  • Identification of critical process parameters
  • Clearance of impurities
  • Establishment of environmental controls to meet safety requirements
  • Thorough characterization of structure, purity, and efficacy

Khaled Yamout, Senior Director, Manufacturing and Quality Control at
TriLink BioTechnologies, will discuss some of these challenges and solutions to support the requirements for characterization of structure, purity, and, efficacy of a well characterized mRNA drug substance.

play

Treating Viral Infections with mRNA-Encoded Cas13

The potential of gene editing as a therapeutic has come to fruition in the past several years, as clinical data from various studies has shown very positive results. Merging that potential with novel mRNA technologies—which have also demonstrated their value and versatility during the COVID-19 pandemic—could provide scientists and clinicians with an unmatched weapon in the arsenal to fight various diseases. In particular, Cas13 has been used to target RNA viruses in cell culture, but only recently has efficacy in animal models been demonstrated.

in this webinar, cohosted by GEN and The CRISPR Journal, that is diving deep into the burgeoning world of mRNA research and therapeutics. Our distinguished guest for this event, Dr. Philip Santangelo, will introduce important aspects of how to use mRNA to express Cas13 and use it as an antiviral agent. Additionally, Dr. Santangelo will discuss guide design, screening, the importance of controls, and how to apply this approach in vivo against multiple pathogens

play

Challenges and Considerations for mRNA Therapeutic Development

Due to its extreme potential to revolutionize the biopharma industry, the benefits of mRNA as a novel therapeutic are well known. However, the path leading to the development of mRNA medicines can be challenging and is often less discussed. Qualities like nucleic acid stability, immunogenicity, and delivery of the final product are all critical factors that face mRNA medicines and need to be addressed more frequently. Thankfully, novel methodologies and techniques to assist drug developers are on the rise and have the potential to streamline production workflows and increase production and efficiency.

This is the second webinar in a series of four, cohosted by GEN and The CRISPR Journal, that is diving deep into the burgeoning world of mRNA research and therapeutics. Our distinguished guest for this event, Dr. Edward Miracco, will take us through his extensive experience with mRNA chemistry, sequence design, and commercial-scale production. Dr. Miracco has faced many challenges in his work and will tell us about several vital considerations that could significantly aid your mRNA research endeavors.

play

Influenza mRNA Vaccines: Mechanisms and Methodologies

The power of mRNA vaccines became well established due to the COVID-19 pandemic, but we are just beginning to scratch the surface of their therapeutic versatility. Numerous global projects are underway to employ mRNA technology to combat human diseases such as cancer, HIV, and influenza. In a four-part webinar series over the next several months, we will hear from a diverse group of investigators who are at the vanguard of mRNA research and the novel ways they are utilizing this technology.

In this first webinar, our distinguished speaker, Dr. Norbert Pardi, will be discussing cutting-edge work on the development of broadly protective mRNA-based influenza vaccines. Not only will he discuss the mechanism of action of mRNA vaccines, Dr. Pardi will also tell us how his laboratory utilized a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine platform to deliver a combination of conserved influenza virus antigens.

play

TIDES mRNA Technologies Digital Week: Analytical Methods for a Well Characterized mRNA Drug Substance

Though much of the regulatory filing requirements for mRNA-based therapeutics can be compared with those for traditional biologics, others are not yet well defined. Like traditional biologic products and processes, mRNA-based products require controls on the quality of the starting material (including cell banking), consistency of manufacturing processes, identification of critical process parameters, clearance of impurities, establishment of environmental controls to meet safety requirements, and the thorough characterization of structure, purity, and efficacy. This has posed some challenges in analytical method development to ensure qualification for intended use. We discuss some of these challenges and solutions to support the requirements for characterization of structure, purity, and efficacy of an mRNA Drug Substance.

DELIVERY

play

Advantages of In vivo DNA Barcoding in Nanoparticle Selection: Quantifying how thousands of nanoparticles deliver nucleic acids in vivo using DNA barcodes.

In this video James Dahlman, PhD, Assistant Professor, Department of Biomedical Engineering at the Georgia Institute of Technology discusses, RNA therapeutics and the role of  in vivo DNA barcoding in nanoparticle selection.

MRNA

play

Vaccine and Trial Efforts Against COVID-19

In this Webinar Dr. Tal Zaks, CMO at Moderna, will discuss vaccine and trial efforts against COVID-19

play

Self-Amplifying mRNA Vaccines for Pandemic Rapid Response

In this webinar, you will hear from Dr. Andy Geall about data innovations from seven years of research at Novartis Vaccines on self-amplifying mRNA technology and how this approach could enable the concept of vaccines on demand as a rapid response to a real threat.

play

SARS-CoV-2: Going Viral

In this Webinar Dr. Gregory A. Poland, Director of Mayo Vaccine Research Group at the Mayo Clinic will discuss, SARS-CoV-2: Going Viral.

play

Coronaviruses in Livestock: Vaccines and International Transport of Virus

In this Webinar Dr. Mark Kehrli, Center Director at the National Animal Disease Center will discuss, Coronaviruses in Livestock: Vaccines and International Transport of Viruses.

play

Base Editing: Putting Precision into Genomic Medicine

In this presentation, Dr. Nicole Gaudelli will discuss how her group has transformed off-the-shelf base editors from a technology developed in academia to a promising therapeutic tool through engineering, screening, and directed evolution.

play

COVID-19: A Prototype Pathogen Demonstration Project for Pandemic Preparedness

In this Webinar Dr. Barney S. Graham, Deputy Director, VRC, NIAID NIH will discuss, COVID-19: A prototype pathogen demonstration project for pandemic preparedness.

play

A CRISPR Vision for the Future of Cell Therapy

In this webinar, T.J. Cradick, PhD, who was until recently head of genome editing at CRISPR Therapeutics, will introduce how genome editing is used to engineer cell therapies.

play

Why Use mRNA: Video 1 of 8 from the TIDES 2018 Workshop by Dr. Anton McCaffrey.

In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses the benefits of using mRNA for manufacturing therapeutics.

play

CRISPR-Based In Vivo Genome Editing and Base Editing

In this webinar, Dr. Wen Xue, Assistant Professor, RNA Therapeutics Institute at the University of Massachusetts Medical School will present, a modular delivery strategy for homology-directed repair by combining lipid nanoparticle delivery of Cas9 mRNA with adeno-associated viruses (AAV) encoding a sgRNA and a repair template.

play

mRNA Applications: Summarizing mRNA applications that include genome engineering, gene replacement, and immunobiology. Part 2 of 8 of the TIDES 2018 workshop series by Dr. Anton McCaffrey.

In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses, mRNA applications, including gene engineering, gene replacement and immunobiology.

play

mRNA Biology: Video 3 of 8 from the TIDES 2018 Workshop featuring Dr. Anton McCaffrey. Includes biology of mRNA location and sensor recognition.

In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses the biology behind mRNA therapeutics.

play

Manufacturing Design Considerations: Video 4 of 8 from the TIDES 2018 Workshop featuring Dr. Anton McCaffrey. Includes: planning the optimal mRNA, mRNA synthesis, mRNA manufacturing processes, research phase, plasmid template, and poly A polymerase.

In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses planning, manufacturing design considerations and processes involved with research and clinical applications.

play

WVC COVID-19 Webinar: Panel on Vaccine Trial Data, Antibodies and Safety

This panel focuses on the lessons learned from COVID-19 vaccine human trials to date: our current understanding on the evolving trial data, neutralizing antibodies and safety of these COVID-19 vaccine candidates.

play

mRNA Capping: Video 5 of 8 from the TIDES 2018 Workshop featuring Dr. Anton McCaffrey. m6Am, Cap 0, Cap 1, and Cap 2 explained in this summary of endogenous cap structures.

In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses the cap structures .m6Am, Cap 0, Cap 1, and Cap 2 for optimal mRNA synthesis.

play

In Vitro mRNA Capping: Video 6 of 8 TIDES 2018 featuring Dr. Anton McCaffrey discussing mRNA capping methods, capping characteristics, ARCA, CleanCap, and comparison data.

In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses the capping characteristics, capping methods and comparison data between legacy capping methods ARCA, and CleanCap®, TriLink’s, novel, new capping technology.

play

Chemical Modification of mRNA: Part 7 of 8 of the TIDES 2018 workshop series by Dr. Anton McCaffrey. Includes topics surrounding modified RNA sequence space, sequence engineering, uridine depletion, purification methods, effect of cap structures, and var

In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses chemical modification of mRNA including purification methods and sequence engineering.

play

Design & Manufacturing of Chemically Modified mRNA Therapeutics: Design and Manufacturing of Chemically Modified Messenger RNA Therapeutics - Entire Video TIDES 2018 Workshop by Dr. Anton McCaffrey

In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses, the Design & Manufacturing of Chemically Modified mRNA Therapeutics: This complete video highlights mRNA therapeutic manufacturing from research to clinical applications.

CGMP

play

The Path to GMP Production: Video 8 of 8 from the TIDES 2018 workshop series by Dr. Anton McCaffrey

In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses, the path to GMP production including planning and timelines.

Items 1 to 30 of 50 total

Page